According to a pre-clinical study by Lefere et al., lanifibranor could provide a superior anti-NAFLD activity than single agonists (fenofibrate (PPAR-α), pioglitazone (PPAR-γ) and GW501516 (PPAR-δ)) in different NAFLD mice models [119]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.